rts logo

Bluebird bio Inc (BLUE) Analysis & Forecast for 2024

Bluebird bio Inc (NASDAQ: BLUE) is -12.32% lower on its value in year-to-date trading and has touched a low of $0.88 and a high of $5.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BLUE stock was last observed hovering at around $1.24 in the last trading session, with the day’s loss setting it -0.03%.

Currently trading at $1.21, the stock is -12.67% and -2.97% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.46 million and changing -2.42% at the moment leaves the stock -54.72% off its SMA200. BLUE registered -61.46% loss for a year compared to 6-month loss of -60.20%. The firm has a 50-day simple moving average (SMA 50) of $16.69 and a 200-day simple moving average (SMA200) of -$2.75.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The stock witnessed a -22.68% gain in the last 1 month and extending the period to 3 months gives it a -12.32%, and is -11.03% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.37% over the week and 10.83% over the month.

Profit margin for the company is -419.62%. Distance from 52-week low is 37.66% and -78.12% from its 52-week high. The company has generated returns on investments over the last 12 months (-20.06%).

Bluebird bio Inc quarterly earnings per share for the current quarter are estimated at -$0.66 with sales reaching $10.8M over the same period.The EPS is expected to grow by 10.66% this year, but quarterly earnings will post 900.60% year-over-year. Quarterly sales are estimated to grow 17,319.40% in year-over-year returns.

Bluebird bio Inc (BLUE) Top Institutional Holders

253 institutions hold shares in Bluebird bio Inc (BLUE), with institutional investors hold 70.88% of the company’s shares. The shares outstanding are 192.74M, and float is at 189.83M with Short Float at 17.93%. Institutions hold 70.61% of the Float.

The top institutional shareholder in the company is State Street Corporation with over 16.36 million shares valued at $53.82 million. The investor’s holdings represent 15.29% of the BLUE Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 8.79 million shares valued at $28.93 million to account for 8.22% of the shares outstanding. The other top investors are Tang Capital Management, LLC which holds 7.38 million shares representing 6.90% and valued at over $24.29 million, while Pfm Health Sciences, Lp holds 6.81% of the shares totaling 7.29 million with a market value of $23.97 million.

Bluebird bio Inc (BLUE) Insider Activity

The most recent transaction is an insider sale by Obenshain Andrew,the company’sPresident and CEO. SEC filings show that Obenshain Andrew sold 6,095 shares of the company’s common stock on Mar 04 ’24 at a price of $1.53 per share for a total of $9311.0. Following the sale, the insider now owns 0.28 million shares.

Bluebird bio Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Klima Thomas Jsold a total of 4,573 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $1.53 per share for $6986.0. Following the transaction, the insider now directly holds 0.12 million shares of the BLUE stock.

Still, SEC filings show that on Mar 01 ’24, Colvin Richard A (Chief Medical Officer) disposed off 6,770 shares at an average price of $1.53 for $10342.0. The insider now directly holds 118,368 shares of Bluebird bio Inc (BLUE).

Related Posts